Psychedelic Therapy in Sweden: Every Legal Route (2026)

If you are considering psychedelic-assisted treatment in Sweden — for yourself or for someone close to you — the picture in July 2026 is defined less by law than by restraint. The medicines exist, the system has assessed them, and the national advisory body has told the regions to hold back. That produces a landscape where the formally approved route is deliberately narrow, the off-label route is quiet and self-paid, and the research route is — unusually for Europe — one of the strongest on offer. This guide covers who qualifies for each route, how to start, what it costs, and what to realistically expect; you can begin orienting yourself with our eligibility check.

TL;DR Spravato (esketamine) is legal in Sweden but the NT Council recommends "strongly restrained" (kraftigt återhållsam) use — its recommendation, first issued 30 June 2021 and revised 6 November 2024, reserves the spray for patients who have tried roughly four other treatment alternatives, and each region decides its own funding, so availability varies across the country. Off-label racemic ketamine for depression exists in some specialist and private settings, with Stockholm private infusions at about 4,500–5,000 SEK each. Psilocybin and MDMA have no medical route, but psilocybin trials are recruiting in five Swedish cities — for cancer-related depression and for anorexia nervosa — which makes the research route unusually real here.

At a glance

Route	Substance	Status in Sweden	Who qualifies	Cost
Esketamine (Spravato)	Esketamine	Legal; NT Council advises strongly restrained use (rev. 11/2024); region-by-region funding	Treatment-resistant depression, in practice after roughly four failed alternatives; specialist psychiatry decides	Public patient fees within the high-cost ceiling where a region funds it
Off-label ketamine	Racemic ketamine	Legal off-label use in some specialist and private settings	Clinic or department screening; typically documented treatment resistance	Private: roughly 4,500–5,000 SEK per infusion in Stockholm, self-pay
Psilocybin therapy	Psilocybin	Research only — but trials recruiting in five cities	Study-specific criteria (cancer-related depression; anorexia nervosa)	Free within a trial
MDMA therapy	MDMA	Research only; no Swedish trial exists	—	—
Clinical trials	Psilocybin, ketamine, esketamine	Several recruiting studies	Study-specific criteria	Free

Esketamine (Spravato): legal, assessed — and deliberately held back

Sweden never rejected Spravato the way England or Norway did. Instead, the NT Council (NT-rådet) — the body that advises all 21 regions on new therapies — issued a recommendation on 30 June 2021, revised on 6 November 2024, that use should be kraftigt återhållsam: strongly restrained (Samverkanläkemedel). The reasoning is documented uncertainty about long-term benefit and side effects relative to price. In practice the recommendation means Spravato only becomes relevant after a run of better-documented options — roughly four treatment alternatives, counting antidepressants, augmentation and, where appropriate, ECT — has been tried and failed.

Two structural facts follow from this, and they decide what you can actually get:

Funding is regional. The NT Council advises; each region decides. Some regions have published local care routines for Spravato in treatment-resistant depression — Region Skåne, for example, maintains a detailed clinical protocol — while others fund little or none. The same diagnosis can meet a different answer in a different county.
Delivery is specialist-only. Spravato is a clinic-administered (rekvisition) medicine given in specialist psychiatry with post-dose observation, never dispensed for home use. Your entry point is a psychiatrist, usually via referral from primary care.

How to start. Ask your vårdcentral for a referral to specialist psychiatry, or approach a psychiatric clinic directly where your region allows self-referral (egenremiss). The practical currency, as everywhere in Europe, is a written treatment history: every antidepressant and augmentation tried in the current episode, with dose, duration and outcome. In a system built on restraint, that document is your case. Where the region funds treatment, you pay ordinary patient fees that count toward the national high-cost ceiling (högkostnadsskydd).

Access pathway for the Swedish specialist route: GP or psychiatrist, hospital psychiatric department, internal protocol decision, hospital-administered treatment with public coverage

Waiting and realism. Even in funding regions, volumes are small and clinics few. Expect the assessment chain — referral, specialist evaluation, internal decision — to take months rather than weeks, and expect your documentation to be scrutinised against the roughly-four-alternatives bar. How Sweden's restraint compares with its neighbours is mapped in our Europe-wide reimbursement guide.

Off-label ketamine: quiet, legal, mostly self-paid

Racemic ketamine is an authorised anaesthetic in Sweden, and prescribing it off-label for depression is legal medical practice. What Sweden lacks is any national funding decision for it — there is no Norwegian-style pathway here. In practice, off-label ketamine treatment for depression exists in two forms:

Some public specialist settings use ketamine within hospital psychiatry — in connection with ECT units, research programmes or individual clinical decisions. Access is at the treating department's discretion and cannot be applied for from outside; if you are already in specialist care, it is a conversation to have with your psychiatrist.
A small private market, concentrated in Stockholm, offers ketamine infusions for treatment-resistant depression on a self-pay basis at roughly 4,500–5,000 SEK per infusion, with a typical induction course of six infusions bringing the medicine cost alone to around 27,000–30,000 SEK before assessment fees. Private treatment is not covered by regional funding or the high-cost ceiling.

Screening comes first in any legitimate setting: psychiatric history, cardiovascular check, medication review, then a treatment decision. A clinic that skips that order is a warning sign, whatever its prices.

Psilocybin: research only — but the trials are real

Psilocybin is a controlled narcotic in Sweden with no medical-access route: no compassionate-use programme, no authorised clinics, and no reimbursement. What Sweden does have — more than most of Europe — is recruiting research. As of July 2026, two psilocybin trials are open:

CAPSI (NCT06319378), a Phase 2 study of a single 25 mg psilocybin dose for cancer-related major depression, led from Northern Stockholm Psychiatry and recruiting at sites in Stockholm, Gothenburg, Uppsala and Örebro.
A Region Skåne study in Lund (NCT07169747) of two psilocybin doses with psychological support in young adults with anorexia nervosa — one of very few anorexia psilocybin trials anywhere.

Participation is free, legal and strictly screened; enrolment is never guaranteed, and placebo or low-dose comparison arms are part of the design. If your situation matches either study population, this is the one route in Sweden where psilocybin therapy is actually happening — browse trial sites in Sweden and see our trials guide for how participation works. Anyone selling psilocybin therapy commercially in Sweden is operating illegally, including retreat formats.

MDMA: not available in any form

MDMA is a controlled substance in Sweden with no medical route, no compassionate-use framework — and, unlike Norway or Finland's neighbours, no Swedish MDMA trial history to point to: Blossom's tracking of Swedish studies shows esketamine, ketamine and psilocybin, not MDMA. As of July 2026 no Swedish MDMA study is recruiting or planned in the public registries. If MDMA-assisted therapy matters to you, the realistic option is trial sites elsewhere in Europe — our trials guide explains how to search. Anyone offering MDMA therapy commercially in Sweden today is breaking the law.

Clinical trials in Sweden

The research route deserves its own summary, because it is Sweden's strongest card. Blossom tracks eight trials connected to Sweden, and the recruiting set in July 2026 spans three compounds: the two psilocybin studies above, and a Phase 2 trial of add-on oral slow-release ketamine in major depression that began in March 2026. Karolinska Institutet anchors much of the ecosystem, including PET-imaging psilocybin research. Sweden also hosted sites in the international esketamine Phase 3 programme (ESCAPE-TRD, SUSTAIN), which is part of why the system's evidence standards are so explicit. Participation is free and legal, with strict screening; see the trials guide for phases, placebo and consent, and search ClinicalTrials.gov for current Swedish listings.

What to expect in treatment

The shape of care is similar across routes. It begins with screening: the clinician reviews your psychiatric and medication history, checks blood pressure and current medicines, and confirms the diagnosis before anything is scheduled. This is where contraindications are caught, and in Sweden it is also where the treatment-resistance documentation is weighed.

On a Spravato day you self-administer the nasal spray at the psychiatric clinic under supervision, then stay for roughly two hours of observation while staff monitor blood pressure, heart rate and how you feel; a detached, dreamlike sensation and a temporary blood-pressure rise are expected effects that settle as the drug clears. Sessions are more frequent during induction and taper by measured response, alongside a continuing oral antidepressant. You must not drive for the rest of the day.

A ketamine infusion runs over about 40–60 minutes with the same monitoring and a recovery period afterwards; private Stockholm providers typically structure six infusions over two to three weeks, with evaluation before and after the course. In a trial, add research measurements, questionnaires and follow-up visits — and the possibility of a comparison arm. In every setting, the medicine is one component: screening, supervision and follow-up are what make it safe, and continuing psychiatric care is what helps the effect last.

Risks and who should not start

These treatments are generally well tolerated under supervision, but they are not for everyone — which is exactly what screening is for. Common, transient effects during or shortly after a session include dissociation, nausea, dizziness and a short-lived rise in blood pressure and heart rate. Treatment may be inappropriate, or require particular caution and specialist evaluation, when any of the following apply:

Uncontrolled hypertension or significant cardiovascular disease, including aneurysmal vascular disease, because of the temporary blood-pressure rise.
A personal or family history of psychosis or bipolar disorder — a particular caution for psilocybin, which the Swedish trials screen for carefully.
Substance-use concerns, particularly patterns of compulsive use; esketamine is classified as a narcotic in Sweden partly for this reason.
Severe liver disease or other serious unstable somatic illness.
Pregnancy or breastfeeding.
Acute suicidality requiring emergency care — crisis services come first; in an emergency call 112 or contact your nearest psykiatrisk akutmottagning.

A responsible provider screens for all of these before the first session. If a clinic will treat you without that assessment, treat it as a warning sign. To see who is listed in Sweden, browse our catalog.

Frequently asked questions

Can I actually get Spravato in Sweden?

Yes, but narrowly. The NT Council's recommendation (revised November 2024) advises strongly restrained use, in practice after roughly four failed treatment alternatives, and each region decides whether to fund it. You need a specialist psychiatry assessment and a documented treatment history; whether treatment follows depends on your region's stance and your clinic's protocol.

Why does availability depend on where I live?

Sweden's 21 regions each make their own funding decisions; the NT Council only advises them. Some regions have published Spravato care routines, others fund little or none. If your region says no, options are a second specialist opinion, a documented individual case, or the research route.

What does private ketamine treatment cost?

In Stockholm, roughly 4,500–5,000 SEK per infusion, self-pay, with a six-infusion course around 27,000–30,000 SEK plus assessment fees. Private treatment sits outside the high-cost ceiling, so nothing is reimbursed. Ask for the full course price in writing before starting.

Can I join a psilocybin trial in Sweden?

If you match a study population, genuinely yes — CAPSI recruits people with cancer-related major depression in Stockholm, Gothenburg, Uppsala and Örebro, and a Lund study recruits young adults with anorexia nervosa. Screening is strict and enrolment is never guaranteed, but these are real, free, legal routes to supervised psilocybin treatment.

Is MDMA therapy available in Sweden?

No — not clinically, not in research. No Swedish MDMA trial exists, and no medical framework allows it. Trial sites elsewhere in Europe are the only legal option.

Does the high-cost ceiling cover any of this?

Public specialist care, including regionally funded Spravato, falls under ordinary patient fees and the high-cost ceiling. Private ketamine clinics and anything self-paid do not count toward it.

Sources

This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Regional funding decisions and trial recruitment change; always verify current requirements with your region, your clinic, or a licensed clinician who knows your history. If you are in crisis, contact 112 or a crisis line immediately.

This guide awaits review by a licensed medical professional.

Psychedelic Therapy in Sweden: Every Legal Route in 2026